Maze Therapeutics (NASDAQ:MAZE) Posts Quarterly Earnings Results

Maze Therapeutics (NASDAQ:MAZE) issued its quarterly earnings data on Monday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01), FiscalAI reports.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE traded up $0.72 on Monday, reaching $34.91. The company’s stock had a trading volume of 510,320 shares, compared to its average volume of 672,201. Maze Therapeutics has a 52-week low of $21.95 and a 52-week high of $53.65. The company has a market cap of $1.94 billion, a P/E ratio of -13.85 and a beta of 2.04. The company has a 50-day simple moving average of $27.79 and a 200 day simple moving average of $31.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MAZE shares. Citigroup assumed coverage on Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. Canaccord Genuity Group initiated coverage on Maze Therapeutics in a report on Monday, October 19th. They set a “buy” rating and a $75.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $64.45.

Insider Buying and Selling at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the transaction, the chief executive officer owned 15,558 shares in the company, valued at approximately $420,377.16. This trade represents a 68.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,141 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at $434,677.13. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 192,991 shares of company stock valued at $5,187,559 over the last quarter. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC increased its position in shares of Maze Therapeutics by 390.5% during the 3rd quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock valued at $30,000 after purchasing an additional 867 shares during the last quarter. Royal Bank of Canada lifted its position in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics during the second quarter worth $48,000. Quantbot Technologies LP purchased a new position in Maze Therapeutics during the second quarter worth $80,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Maze Therapeutics during the third quarter valued at $77,000.

About Maze Therapeutics

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.